Novo Nordisk has started building its first brand-new manufacturing facility in Denmark since the millennium, saying it plans to spend around DKK 8.5 billion ($1.2 billion) on the plant.

This week's stock market saw the S&P 500 rise 3.4%, fueled by positive inflation data and strong earnings reports.

The transaction – first announced in February – would see Novo Nordisk's parent company Novo Holdings buy contract development and manufacturing ... to stop using the plants to produce ...

Following the acquisition, Novo Holdings sold three of Catalent's plants utilized in drug manufacturing to Novo Nordisk for $11 billion. This strategic sale is aimed at boosting supplies of Novo ...

Gov. Gavin Newsom’s ambitious plan to produce a cheap, generic insulin for the 3.2 million Californians with diabetes is behind the schedule he announced ...

It's still investing billions in spinning up new manufacturing facilities to ensure that supply capacity stops being a constraint on growth. What's more, Novo Nordisk is in exactly the same ...

It hasn't been a great period for investors in Novo Nordisk (NYSE: NVO) despite its ongoing status as one of the pharmaceutical industry's apex competitors in the field of cardiometabolic drugs.

Whales with a lot of money to spend have taken a noticeably bullish stance on Novo Nordisk. Looking at options history for Novo Nordisk (NYSE:NVO) we detected 21 trades. If we consider the ...

Medicare is preparing to negotiate prices on GLP-1 drugs such as Ozempic. Novo Nordisk investors could see the news put $14.3 billion in Medicare revenue at risk. Viking Therapeutics stock ...

The Centers for Medicare and Medicaid Services (CMS) released its second round of drug negotiation targets, a list of 15 drugs under Medicare Part D, including Novo Nordisk's (NVO) blockbuster GLP-1s.

Novo Nordisk's GLP-1 weight loss drugs, Ozempic and Wegovy, will be targeted in the next round of Medicare price negotiations in 2027, along with 13 other medications.Seana Smith and Brad Smith ...